Article
Envision Pharma Group
The Role of MSLs in Achieving Health Equity
Summary
In this episode, Ariel Katz, co-founder of H1, joins Tom Caravela to discuss the crucial topic of health equity. Ariel shares insights into his background and the mission of H1, defining health equity and exploring the causes of healthcare inequity. The conversation delves into the roles of MSLs and leadership in promoting health equity and highlights the actions pharmaceutical companies can take, emphasizing patient advocacy. The discussion also covers the impact of stricter FDA regulations on future MSL engagement and the importance of engaging with low and middle-income communities. Ariel offers final thoughts on raising awareness and building trust in healthcare.
My guest today is Ariel Katz, CEO and Founder of H1 and we discuss the role of MSLs in achieving Health Equity.
This episode is sponsored by H1, for info please visit www.H1.co
Ariel shares…
👉 His definition of health equity and why it has become a problem
👉 How MSLs fit into the equation for health equity and what can they do
👉 What pharma and biotech companies can do to assist in this effort to achieve health equity
👉 What patients need to be aware of and what can they do to help themselves
👉 The role of the FDA and what regulators can and should be doing
health equity, healthcare inequity, pharmaceutical companies, patient advocacy, FDA regulations
Related Topics
You May Also Like
Envision Pharma Group
Article
S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
Article
Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois
Sponsorship of oncology clinical trials in the United States according to age of eligibility
Article
Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
Article
Karen Geary
Finding the Right Drug at the Right Dose the First Time: Has the Era of Personalized Formularies Finally Arrived?
Article
J. Remon, R. García-Campelo, E. de Álava, R. Vera, J. L. Rodríguez-Peralto, Á. Rodríguez-Lescure, B. Bellosillo, P. Garrido, F. Rojo & R. Álvarez-Alegret